Vaxcyte, Inc. business relationships
Companies named in Vaxcyte, Inc.’s 10-K filed 2026-02-24, and public companies whose annual reports name Vaxcyte, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.7 / 10
- AI naming
- 10 / 100 Top 4% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Vaxcyte, Inc.’s annual report 6
“PPSV23, manufactured and marketed by Merck is the only pneumococcal polysaccharide vaccine widely available.” SEC filing
“In February 2026, SK bioscience announced that it expected topline results from this Phase 3 study to be available in 2027, and that a next-generation PCV candidate, also co-developed with Sanofi, was in preclinical development with clinical trial entry expected in 2026.” SEC filing
“For details of the Commercial Manufacturing and Supply Agreements with Lonza and Thermo Fisher, see Note 4.” SEC filing
“...ary eCRM protein carrier is produced using our cell-free protein synthesis platform, which is exclusively licensed from Sutro Biopharma for the Vaccine Field (as defined in the Sutro Biopharma License Agreement (as defined below)). eCRM, contains multiple copies of non-native para azido-methyl-pheny...” SEC filing
“In May 2018, we entered into a supply agreement with Sutro Biopharma, which was subsequently amended on February 22, 2021 and November 21, 2023 (as amended, the "Sutro Biopharma Supply Agreement") pursuant to which we purchase from Sutro Biopharma extract and custom reagents for use in manufacturing...” SEC filing
“Commercial Manufacturing and Supply Agreement by and between the Registrant and Lonza Ltd., dated October 13, 2023.” SEC filing
Companies whose annual reports name Vaxcyte, Inc. 5
“For the years ended December 31, 2025 and 2024 , the agreed-upon reimbursements by Vaxcyte of the costs associated with such arrangements, principally for pass-through costs from the CMOs, were $ 1.2 million and $ 9.0 million, respectively, and were accounted for by the Company as a reduction to res...” SEC filing
“As such, we retain the revenue interest in royalties from Vaxcyte on sales of all products other than a PCV product, such as VAX-24 or VAX-31.” SEC filing
“Under the license agreement, Vaxcyte has the right to use the XpressCF ® and XpressCF+ ® platforms to discover and develop vaccine candidates for the treatment or prophylaxis of infectious diseases.” SEC filing
“Our existing collaborations with Astellas and Vaxcyte are important to our business.” SEC filing
“Collaboration and License Agreements and Supply Agreements, Vaxcyte Agreement, following agreement with Vaxcyte on the Form Definitive Agreement and upon effectiveness of the amendment No. 3 to the 2015 License Agreement, the revenue interest in the 4 % royalty on potential future net sales of Vaxcy...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.